Erin Lichy Gets Real About Her Natrelle® Breast Augmentation [TheStreet.com]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: TheStreet.com
April 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) has teamed up with New York-based entrepreneur and television personality, Erin Lichy. Lichy is opening up about her recent breast augmentation with market-leading Natrelle ® breast implants in an effort to promote transparency and normalize conversations around aesthetic procedures. As a mom of four, and after years of breastfeeding, Lichy's decision to pursue breast augmentation is a part of her personal journey towards renewed body positivity. By sharing her story, Lichy aims to support other women considering breast surgery. "Motherhood and breastfeeding changed my body in ways I didn't fully expect, and I found myself wanting to feel more like me again," said Erin Lichy. "I didn't originally consider breast implants because I was looking for an understated result, but after sharing my aesthetic goals with board-certified plastic surgeon Dr. Ira Savetsky, we chose Natrelle ® implants. It was a ver
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Why AbbVie Is a No-Brainer Stock to Buy on the Dip [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Erin Lichy Gets Real About Her Natrelle® Breast AugmentationPR Newswire
- Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for PainPR Newswire
- AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026PR Newswire
- AbbVie (ABBV) had its price target raised by Guggenheim from $242.00 to $249.00. They now have a "buy" rating on the stock.MarketBeat
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 4/3/26 - Form 8-K
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- ABBV's page on the SEC website